Issac Vilchis

Data Science Bootcamp

September 25, 2019

Pymaceuticals

In the program of pandas, there were three observable trends based on the data. The first trend is how the tumor responded to the treatment. From the data, Capomulin has decreased over time while Infubinol, Ketapril, and Placebo have increased. Infubinol fluctuates as it increases while Placebo and Ketapril do not. For the metastatic response section, the metastatic sites start out at zero, unlike the tumor response which start out at forty-five. All of the metastatic sites of the drugs fluctuate when they increase over time. Ketapril increases further than Infubinol and Capomulin and may increase further than Placebo. When looking at the data for the survival rates, it presents that those with Capomulin have survived the most while Infubinol seem to be the most dangerous. Ketapril and Placebo seem to be at a similar count at the end of the graph. After creating the summary of the data and the summary bar graph, Capomulin has a 19.475% decrease in the tumor response while the other drugs have an increase percentage of over 46.123%, 57.029, and 51.2979 for the Infubinol, Ketapril, and Placebo drugs respectively. This presents that change in the change of percentages in four of the drugs for the treatment.